Monrovia-based Xencor, the biopharmaceuticals firm headed by Dr. Bassil Dahiyat, has inked a licensing deal with German pharmaceuticals firm MorphoSys, Morphosys said over the weekend. Accordin to MorphoSys, it has gained an worldwide license to XmAb5574, a high potency monoclonal antibody developed by Xencor for the treatment of B-cell malignancies. As part of the licensing deal, Xencor will receive $13M and will be eligible for unspecified development-, regulatory- and commercialization-related milestone payments and royalties. The compound is being used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia. Xencor is venture backed by HealthCare Ventures, MedImmune Ventures, Merlin Nexus, Novo Nordisk, Oxford Bioscience Partners, Stafford Investments, and Zen Investments.
Top NewsMonday, June 28, 2010
Xencor In License With MorphoSys